

PTO-854 PCT/US 21 JUL 2006

PTO/SB/21 (09-04)

Approved for use through 07/31/2006 OMB 0651-0031  
U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it displays a valid OMB control number.

# TRANSMITTAL FORM

(to be used for all correspondence after initial filing)

Total Number of Pages in This Submission


19

Application Number	10/572,778
Filing Date	March 21, 2006
First Named Inventor	Stefan Berg, et. al.
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	101192-1P US

## ENCLOSURES (Check all that apply)


<input type="checkbox"/> Fee Transmittal Form <input type="checkbox"/> Fee Attached  <input type="checkbox"/> Amendment/Reply <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)  <input type="checkbox"/> Extension of Time Request  <input type="checkbox"/> Express Abandonment Request <input checked="" type="checkbox"/> Information Disclosure Statement  <input type="checkbox"/> Certified Copy of Priority Document(s)  <input type="checkbox"/> Reply to Missing Parts/ Incomplete Application <input type="checkbox"/> Reply to Missing Parts under 37 CFR 1.52 or 1.53	<input type="checkbox"/> Drawing(s) <input type="checkbox"/> Licensing-related Papers  <input type="checkbox"/> Petition <input type="checkbox"/> Petition to Convert to a Provisional Application <input type="checkbox"/> Power of Attorney, Revocation <input type="checkbox"/> Change of Correspondence Address  <input type="checkbox"/> Terminal Disclaimer <input type="checkbox"/> Request for Refund  <input type="checkbox"/> CD, Number of CD(s) _____ <input type="checkbox"/> Landscape Table on CD	<input type="checkbox"/> After Allowance Communication to TC <input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences <input type="checkbox"/> Appeal Communication to TC (Appeal Notice, Brief, Reply Brief) <input type="checkbox"/> Proprietary Information <input type="checkbox"/> Status Letter <input checked="" type="checkbox"/> Other Enclosure(s) (please identify below): International Search Report International-Type Search Report 24 References
Remarks		

## SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT

Firm Name	AstraZeneca Pharmaceuticals (address associated with Customer No. 22466)		
Signature			
Printed name	Karen H. Kondrad		
Date	July 18, 2006	Reg. No.	38,212

## CERTIFICATE OF TRANSMISSION/MAILING

I hereby certify that this correspondence is being facsimile transmitted to the USPTO or deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on the date shown below:

Signature			
Typed or printed name	Marie M. Grelach	Date	July 18, 2006

This collection of information is required by 37 CFR 1.5. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.11 and 1.14. This collection is estimated to 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Application No.: 10/572,778	Applicant: Stefan Berg, et. al.
371 Filing Date: March 21, 2006	Attorney Docket No.: 101192-1P US
Examiner: Not Known	Group Art Unit : Not Known
Customer No.: 22466	Confirmation No.: Not Known
Title: 3-Heterocycl-Indole Derivatives as Inhibitors of Glycogen Synthase Kinase-3 (GSK3)	

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to: Mail Stop PCT, Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450 on 7-18-06

  
\_\_\_\_\_  
Signature  
Marie M. Grelach

Mail Stop PCT  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

**INFORMATION DISCLOSURE STATEMENT**

Sir,

Applicants submit herewith a list of patents and publications pursuant to the duty to disclose in accordance with 37 C.F.R. § 1.56.

In accordance with 37 C.F.R. § 1.97 (g) and (h), the filing of this Information Disclosure Statement shall not be construed as a representation that a search has been made or that the information cited is material to patentability as defined in 37 C.F.R. § 1.56.

In accordance with the U.S. Patent Office's partial waiver of the requirement under 37 C.F.R. 1.98(a)(2)(i), only copies of the foreign patent documents and non-patent publications are enclosed.

**REMARKS**

In accordance with the provisions of 37 C.F.R. 1.97, this statement is being filed:

- (1) within three (3) months of the **filing date** of a national application other than a continued prosecution application under 37 C.F.R. 1.53(d), or within three (3) months of the **date of entry of the national stage** as set forth in 37 C.F.R. 1.491 in an international application, or before the mailing of the **first Office Action** on the merits, or before the mailing of a **first Office Action** after the filing of a request for continued examination under 37 C.F.R. 1.114; or
- (2) after the period defined in (1) but before the mailing date of a **final Action** or a **Notice of Allowance** under 37 C.F.R. 1.311, and
  - the requisite Statement is below, **OR**
  - the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. , referencing Attorney Docket No. , or
- (3) after the mailing date of a **final Action** or **Notice of Allowance** but before the payment of the **Issue Fee**, **AND**
  - the requisite Statement is below, **AND**
  - the Commissioner is hereby authorized to charge the requisite fee under 37 C.F.R. 1.17(p), namely **\$180.00** to deposit account No. , referencing Attorney Docket No. , or

It is respectfully requested that each of the patents and publications listed on the attached Form SB08, and other information contained herein, be considered by the Examiner and made of record in this application

Although Applicants believe no fees are due, the Commissioner is hereby authorized to charge any deficiency in the fees or credit any overpayment to deposit account No. 26-0166 referencing Attorney Docket No. 101192-1P US.

**STATEMENT**

As required under 37 C.F.R. 1.97(e), Applicant(s), through the undersigned, hereby state either that:

- (1) Each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign application **not more than three months** prior to the filing of the Information Disclosure Statement; or
- (2) No item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing this Statement after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to **any individual** designated in 37 C.F.R. 1.56(c) **more than three months** prior to the filing of the Information Disclosure Statement.

Respectfully submitted,



Name: Karen H. Konrad  
Dated: July 18, 2006  
Reg. No.: 38,212  
Phone No.: 302.886.8975

Global Intellectual Property, Patents,  
AstraZeneca,  
1800 Concord Pike,  
Wilmington,  
DE-19850-5437

Enclosures: Form SB08A  
Form SB08B

U.S. Patent and Trademark Office; U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet

of 12

**Complete if Known**

Application Number	10/572,778
Filing Date	March 21, 2006
First Named Inventor	Stefan Berg
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	101192-1P US

**U. S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT					
Examiner Initials*	Cite No.	Foreign Patent Document Country Code <sup>2</sup> , Number <sup>4</sup> , Kind Code <sup>3</sup> (If known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
/K.B./	A1	WO 03/055877 A1	07-10-2003	Stefan Berg, et. al.	
	A2	WO 03/055492 A1	07-10-2003	Stefan Berg, et. al.	
	A3	WO 03/053330 A2	07-03-2003	Stefan Berg, et. al.	
	A4	WO 02/30868 A1	04-18-2002	Gribkoff, et. al.	
	A5	WO 01/27081 A1	04-19-2001	Heckel, et. al.	
	A6	WO 03/082853 A1	10-09-2003	Stefan Berg, et. al.	

Examiner Signature	/Kristin Bianchi/	Date Considered	04/16/2009
--------------------	-------------------	-----------------	------------

Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Consideration is given by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, and will be used to determine the cost of processing your application at the USPTO. The time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND ITO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

U.S. Patent and Trademark Office, U.S. DEPARTMENT OF COMMERCE

Substitute for form 1449/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

Sheet 2 of 2

**Complete if Known**

Application Number	10/572,778
Filing Date	March 21, 2006
First Named Inventor	Stefan Berg
Art Unit	Not Known
Examiner Name	Not Known
Attorney Docket Number	101192-1P LIS

She

cl

#### **U. S. PATENT DOCUMENTS**

## FOREIGN PATENT DOCUMENTS

FOREIGN PATENT DOCUMENT					
Examiner Initials*	Cite No.*	Foreign Patent Document Country Code <sup>a</sup> * Number * Kind Code <sup>a</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages Or Relevant Figures Appear
/K.B./	A7	WO 97/42187	11.13.1997	Thornas, et. al.	*
	A3				
	A4				
	A5				
	A6				

Examiner Signature /Kristin Bianchi/ Date Considered 04/16/2009  
\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and no considered. Include copy of this form with next communication to applicant. \*Applicant's unique citation designation number (optional). See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. \*Enter Office that issued the document, by the two-letter code (WIPO Standard ST.1). For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. \*Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. \*Applicant is to place a check mark here if English language

Translation is attached.  
This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and maintaining the information applicable from the USPTO. Time will vary depending upon the individual case. Any comments or suggestions you have to improve this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO				Complete if Known	
<b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  <i>(Use as many sheets as necessary)</i>		<b>Application Number</b>		10/572,778	
		<b>Filing Date</b>		March 21, 2006	
		<b>First Named Inventor</b>		Stefan Berg	
		<b>Art Unit</b>		Not Known	
		<b>Examiner Name</b>		Not Known	
Sheet	1	of	2	Attorney Docket Number	
101192-1P US					

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
/K.B./	A8	Imahori and Uchida, "Physiology and Pathology of Tau Protein Kinases in Relation to Alzheimer's Disease", J. Biochem, Vol. 121, page 179-188, 1997	
	A9	Hoshi, et al., "Regulation of Mitochondrial pyruvate . . . Kinase 3β in Brain", PNAS, vol. 93, pages 2719-2723, 1996	
	A10	Bhat, et. al., "Regulation and Localization of Tyrosine . . . Neuronal Degeneration", PNAS, vol. 97, page 11074-11079, 2000	
	A11	Stambolic, et. al., "Lithium Inhibits Glycogen Synthase . . . in Intact Cells", Curr. Biol., Vol. 6, pages 1664-1668, 1996	
	A12	Klein and Melton, "A Molecular Mechanism for the Effect of Lithium on Development", PNAS, vol. 93, page 8455-8459, 1996	
	A13	Kozlovsky, et. al., "Low GSK-3β Immunoreactivity . . . of Schizophrenic Patients", Am. J. Psychiatry 2000 May, Vol 157(5), page 831-833	
	A14	Cotter, et. al., "Abnormalities of Wnt Signalling . . . Neurodevelopmental Abnormality", Neuroreport, vol. 9, page 1379-1383, 1998	
	A15	Nikouolina, et. al., "Potential Role of Glycogen . . . of Type 2 Diabetes", Diabetes 2000 Feb., Vol 49(2), pages 263-271	
	A16	Gat, et. al., "De Novo Hair Follicle . . . a Truncated β-Catenin in Skin", Cell, 1998 Nov. 25, vol. 95(5), page 605-614	
↓	A17	Vijayaraghavan, et. al., "A Role for Phosphorylation . . . Motility Regulation", Biol. Reprod., 2000 June, vol. 62(6), page 1647-1654	

Examiner Signature	/Kristin Bianchi/	Date Considered	04/16/2009
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

This collection of information is being conducted by 37 CFR 1.29. The information is required to obtain or retain a benefit in the public which will be filed (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
		<b>Application Number</b>	10/572,778
		<b>Filing Date</b>	March 21, 2006
		<b>First Named Inventor</b>	Stefan Berg
		<b>Art Unit</b>	Not Known
		<b>Examiner Name</b>	Not Known
Sheet	2	of	2
		<b>Attorney Docket Number</b>	
		101192-1P US	

<b>NON PATENT LITERATURE DOCUMENTS</b>				
Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.		T <sup>2</sup>
/K.B./	A18	Naegeli, et al., "2-Amino-Pyridin-5- . . . Abkommlinge", Helv. Chim. Acta., Vol. 21, pages 1746-1756, 1938		
	A19	Sun, et al., "Identification of Substituted 3- . . . Tyrosine Kinases", J. Med. Chem. Bol. 43(14), pages 2655-2663 (2000)		
	A20	Tilley, et al., "Synthesis of Heterocyclic Analogs of $\alpha$ -Methylldopa", J. Heterocyclic Chem., Vol. 16, Pages 333-337, 1979		
	A21	Krapcho, et. al., "Antispasmodics. I. Basic Amides of Benzilic Acid", J. Am. Chem. Soc., Vol. 77, pages 3632-3634, 1955		
	A22	Li Sun, et. al., "Design, Synthesis, and Evaluations of Substituted . . . Tyrosine Kinases", J. Med Chem., Vol 42, pages 5120-5130, 1999		
	A23	L. Thunus, "Synthese et Proprietes . . . (Substitution 2,5) (*)", Annales Pharmaceutiques Francaises, vol. 35, pages 197-204, 1977		
↓	A24	Tobias, et. al., "Novel Therapeutic Targets in Osteoporosis", Expert Opinion on Therapeutic Targets, Feb 2002, pages 41-46		

Examiner Signature	/Kristin Bianchi/	Date Considered	04/16/2009
--------------------	-------------------	-----------------	------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.